MABF96
Anti-TRAcP Antibody, clone 9C5
clone 9C5, from mouse
Synonym(s):
Tartrate-resistant acid phosphatase type 5, TR-AP, Tartrate-resistant acid ATPase, TrATPase, Type 5 acid phosphatase
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
mouse
Quality Level
antibody form
purified antibody
antibody product type
primary antibodies
clone
9C5, monoclonal
species reactivity
human
technique(s)
ELISA: suitable
dot blot: suitable
immunocytochemistry: suitable
immunohistochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable
isotype
IgG2bκ
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... ACP5(54)
General description
Tartrate-resistant acid phosphatase type 5 (TRAcP), also referred to as Acp5, is secreted by osteoclasts during bone resorption. Release of TRAcP was stimulated by resorbogenic cytokines and repressed by calcitonin (a resorption inhibitor). TRAcP is also known to be expressed in high quantities in active macrophages and dendritic cells and play an essential part in presenting antigens to T cells. Inactive TRAcP released from adipose tissue macrophages has been shown to bring on hyperplastic obesity, keeping lipid metabolism and insulin sensitivity normal.
Immunogen
Full length purified protein corresponding to human TRAcP.
Application
Anti-TRAcP Antibody, clone 9C5 detects level of TRAcP & has been published & validated for use in IH, IP, DB, ELISA, IC & WB.
Research Category
Inflammation & Immunology
Inflammation & Immunology
Research Sub Category
Inflammation & Autoimmune Mechanisms
Inflammation & Autoimmune Mechanisms
Western Blot Analysis: A representative lot was used by an independent laboratory in WB. (Janckila, A.J., et al. (1995). Blood. 85:2839-2844.)
Immunoprecipitation Analysis: A representative lot was used by an independent laboratory in IP. (Janckila, A.J., et al. (1995). Blood. 85:2839-2844.)
Dot Blot Analysis: A representative lot was used by an independent laboratory in DB. (Janckila, A.J., et al. (1995). Blood. 85:2839-2844.)
ELISA Analysis: A representative lot was used by an independent laboratory in ELISA. (Janckila, A.J., et al. (1995). Blood. 85:2839-2844.)
Immunocytochemistry Analysis: A representative lot was used by an independent laboratory in IC. (Janckila, A.J., et al. (1996). The Journal of Histochemistry and Cytochemistry. 44(3):233-244.)
Immunoprecipitation Analysis: A representative lot was used by an independent laboratory in IP. (Janckila, A.J., et al. (1995). Blood. 85:2839-2844.)
Dot Blot Analysis: A representative lot was used by an independent laboratory in DB. (Janckila, A.J., et al. (1995). Blood. 85:2839-2844.)
ELISA Analysis: A representative lot was used by an independent laboratory in ELISA. (Janckila, A.J., et al. (1995). Blood. 85:2839-2844.)
Immunocytochemistry Analysis: A representative lot was used by an independent laboratory in IC. (Janckila, A.J., et al. (1996). The Journal of Histochemistry and Cytochemistry. 44(3):233-244.)
Quality
Evaluated by Immunohistochemistry in large malignant B-cells in hairy cell leukemia tissue.
Immunohistochemistry Analysis: 1:500 dilution of this antibody detected TRAcP in large malignant B-cells in hairy cell leukemia tissue.
Immunohistochemistry Analysis: 1:500 dilution of this antibody detected TRAcP in large malignant B-cells in hairy cell leukemia tissue.
Target description
36 kDa calculated
Physical form
Format: Purified
Protein G
Purified mouse monoclonal IgG2bκ in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.
Storage and Stability
Stable for 1 year at 2-8°C from date of receipt.
Analysis Note
Control
Large malignant B-cells in hairy cell leukemia tissue
Large malignant B-cells in hairy cell leukemia tissue
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Christina Møller Andreasen et al.
Bone, 173, 116787-116787 (2023-05-08)
Although failure to establish a vascular network has been associated with many skeletal disorders, little is known about what drives development of vasculature in the intracortical bone compartments. Here, we show that intracortical bone resorption events are coordinated with development
Xenia G Borggaard et al.
Frontiers in molecular biosciences, 9, 896841-896841 (2022-07-02)
The strictly regulated bone remodeling process ensures that osteoblastic bone formation is coupled to osteoclastic bone resorption. This coupling is regulated by a panel of coupling factors, including clastokines promoting the recruitment, expansion, and differentiation of osteoprogenitor cells within the
Nicolai Ernlund Lassen et al.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 32(7), 1395-1405 (2017-02-09)
It is well known that bone remodeling starts with a resorption event and ends with bone formation. However, what happens in between and how resorption and formation are coupled remains mostly unknown. Remodeling is achieved by so-called basic multicellular units
Annika Nordstrand et al.
International journal of molecular sciences, 19(4) (2018-04-20)
Advanced prostate cancer frequently metastasizes to bone and induces a mixed osteoblastic/osteolytic bone response. Standard treatment for metastatic prostate cancer is androgen-deprivation therapy (ADT) that also affects bone biology. Treatment options for patients relapsing after ADT are limited, particularly in
Annika Nordstrand et al.
Clinical & experimental metastasis, 34(3-4), 261-271 (2017-04-28)
Prostate cancer (PCa) patients with bone metastases are primarily treated with androgen deprivation therapy (ADT). Less pronounced ADT effects are seen in metastases than in primary tumors. To test if acute effects of ADT was enhanced by concurrent inhibition of
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service